Hastane personelinde COVID-19 aşı uygulamasının ardından gözlenen aşı sonrası istenmeyen etkilerin ve antikor düzeylerinin değerlendirilmesi
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi 'nde çalışan sağlık personelinde inaktif COVID-19 aşısının yan etki profilini belirlemek ve yapılan aşıların antikor oluşturma düzeylerini tespit etmek amaçlanmıştır. Yöntem: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi 'nde 28 Şubat – 19 Eylül 2021 tarihleri arasında yapılan kohort tipteki bu araştırmada, 396 katılımcıya, yüz yüze görüşme yöntemiyle anket uygulanmıştır. Anket formunda katılımcıların CoronaVac aşısı sonrası yaşadığı yan etkiler sorgulanmıştır. Anket uygulanan 396 katılımcıdan basit rastgele yöntemle seçilen 50 katılımcıya 2 doz CoronaVac aşısı sonrası antikor ölçümü, bu ölçümden 5 ay sonra 3.doz aşı olan ve olmayan ve 2.kez antikor düzeyi bakılmasını kabul eden 30 katılımcıya tekrar antikor ölçümü yapılarak ölçüm sonuçları değerlendirilmiştir. Bulgular: Bu çalışmada hastane personelinin yaş ortalaması 34,37±9,06 idi. CoronaVac aşısı olan katılımcıların %61,9'unda aşı sonrası istenmeyen etkiler (ASİE) görüldüğü, katılımcıların ASİE nedeniyle %1,5'inin ilk doz aşıdan sonra, %1,0'ının 2.doz aşıdan sonra herhangi bir sağlık kuruluşuna başvurduğu saptandı. Aşı sonrası meydana gelen yan etkilerin büyük oranda ilk 24 saat içerisinde meydana geldiği tespit edildi. Katılımcılarda en sık görülen yan etkiler %30,0 ile aşı yapılan kolda ağrı-uyuşma, %25,0 ile halsizlik, %19,6 ile yorgunluk ve %19,6 ile baş ağrısı olarak belirlendi. ASİE görülme oranının kadınlarda, alerji öyküsü olanlarda ve hastalar ile daha yakın planda çalışan personelde daha yüksek olduğu tespit edildi. Katılımcıların 2 doz CoronaVac aşısından 1 ay sonra seropozitiflik oranı %100,0 olarak bulundu. Antikor düzeyi ölçülen katılımcıların 2 doz CoronaVac aşısından 1 ay sonra ölçülen antikor düzeyi 128,85 U/ml, 3.doz aşı yaptırmayan katılımcıların 2.doz aşıdan 6 ay sonra ölçülen antikor düzeyi 60,50 U/ml, 3.doz aşısını CoronaVac yaptıran katılımcıların 3.doz aşıdan 1 ay sonra ölçülen antikor düzeyi 2037,50 U/ml, 3.doz aşısını Biontech yaptıran katılımcıların 3.doz aşıdan 1 ay sonra ölçülen antikor düzeyleri 16869,00 U/ml olarak bulundu. Katılımcılardan 3.doz aşı yaptırmayanların 2.doz aşıdan 6 ay sonra ölçülen antikor seviyelerinin, 2.doz aşıdan 1 ay sonra ölçülen antikor seviyelerine göre düşük olduğu ancak istatistiksel olarak anlamlı bir fark olmadığı tespit edildi (p>0,05). Katılımcılardan 3.doz aşısını mRNA aşısı olan Biontech yaptıran grubun antikor düzeyleri, 3.doz aşısını olmayan ve 3.doz aşısını CoronaVac yaptıran gruplara göre istatistiksel olarak anlamlı yüksek saptandı (p<0,001). Sonuç: CoronaVac aşısı sonrası gelişen yan etkilerin hafif ve orta düzeyde olduğu saptanmıştır. CoronaVac aşısının kişilere güvenle uygulanabileceği öngörülmüştür. Aşı sonucu oluşan antikorların belli süre sonra azalma gösterdiği bu nedenle de rapel dozun gerekli olduğu düşünülmüştür. İki doz CoronaVac ile aşılanmış ve 3.doz aşısını mRNA aşısı olarak tercih eden katılımcıların bağışıklık tepkisinin, 3.doz aşısını CoronaVac olarak tercih eden katılımcılardan çok daha yüksek olduğu tespit edilmiştir. Anahtar Kelimeler: Sars-CoV-2, COVID-19 Aşıları, istenmeyen etkiler, antikorlar
In this study, it was aimed to determine the side effect profile of the inactivated COVID-19 vaccine and to determine the antibody formation levels of the vaccines in the healthcare personnel working at Necmettin Erbakan University Meram Medical Faculty Hospital. Method: Necmettin Erbakan University Meram Faculty of Medicine '28 February – 19 September 2021, this is a cohort type of meeting, with 396 people face-to-face examination. Questionnaire was made about death after CoronaVac vaccine. The accuracy of the used 396 applied simple questionnaire was confirmed by 50 users, whose accuracy was re-read on 30 lines, which were accepted to be tested for the second time, after 2 doses of Corona vaccine, but 5 months after the measurement. Results: The mean age of the hospital staff in this study was 34.37±9.06 years. It was determined that 61.9% of the participants who had CoronaVac vaccine had post vaccine side efects (PVSE), 1.5% of the participants applied to a health institution after the first dose of vaccine and 1.0% after the second dose of vaccine due to PVSE. It was determined that the side effects that occurred after the vaccine mostly occurred within the first 24 hours. The most common side effects in the participants were pain-numbness in the vaccinated arm with 30.0%, fatigue with 25.0%, fatigue with 19.6% and headache with 19.6%. It was determined that the incidence of PVSE was higher in women, those with a history of allergy, and patients and staff working more closely. The seropositivity rate of the participants was found to be 100.0% one month after 2 doses of CoronaVac vaccine. The antibody level measured 1 month after 2 doses of CoronaVac vaccine of the participants whose antibody level was measured was 128.85 U/ml, the antibody level measured 6 months after the 2nd dose of vaccine was 60.50 U/ml of the participants who did not receive the 3rd dose of CoronaVac vaccine, and those who had the 3rd dose of CoronaVac vaccine The antibody level of the participants, which was measured 1 month after the 3rd dose of vaccine, was found to be 2037.50 U/ml, and the antibody levels of the participants who had the 3rd dose of Biontech, measured 1 month after the 3rd dose of vaccine, were 16869.00 U/ml. It was determined that the antibody levels measured 6 months after the 2nd dose of vaccination of the participants who did not receive the third dose of vaccine were lower than the antibody levels measured 1 month after the 2nd dose of vaccine, but there was no statistically significant difference (p>0.05). The antibody levels of the group that received the 3rd dose of Biontech vaccine from the participants were found to be statistically significantly higher than the groups that did not receive the 3rd dose of vaccine and the 3rd dose of CoronaVac vaccine (p<0.001). Conclusion: It was determined that the side effects that developed after CoronaVac vaccine were mild to moderate. It is predicted that the CoronaVac vaccine can be safely administered to individuals. The antibodies formed as a result of the vaccine show a decrease after a certain period of time, so a booster dose was considered necessary. It was determined that the immune response of the participants who were vaccinated with two doses of CoronaVac and who preferred the 3rd dose vaccine as the mRNA vaccine was much higher than the participants who preferred the 3rd dose vaccine as CoronaVac. Keywords: Sars-CoV-2, COVID-19 vaccines, advers effect, antibodies
In this study, it was aimed to determine the side effect profile of the inactivated COVID-19 vaccine and to determine the antibody formation levels of the vaccines in the healthcare personnel working at Necmettin Erbakan University Meram Medical Faculty Hospital. Method: Necmettin Erbakan University Meram Faculty of Medicine '28 February – 19 September 2021, this is a cohort type of meeting, with 396 people face-to-face examination. Questionnaire was made about death after CoronaVac vaccine. The accuracy of the used 396 applied simple questionnaire was confirmed by 50 users, whose accuracy was re-read on 30 lines, which were accepted to be tested for the second time, after 2 doses of Corona vaccine, but 5 months after the measurement. Results: The mean age of the hospital staff in this study was 34.37±9.06 years. It was determined that 61.9% of the participants who had CoronaVac vaccine had post vaccine side efects (PVSE), 1.5% of the participants applied to a health institution after the first dose of vaccine and 1.0% after the second dose of vaccine due to PVSE. It was determined that the side effects that occurred after the vaccine mostly occurred within the first 24 hours. The most common side effects in the participants were pain-numbness in the vaccinated arm with 30.0%, fatigue with 25.0%, fatigue with 19.6% and headache with 19.6%. It was determined that the incidence of PVSE was higher in women, those with a history of allergy, and patients and staff working more closely. The seropositivity rate of the participants was found to be 100.0% one month after 2 doses of CoronaVac vaccine. The antibody level measured 1 month after 2 doses of CoronaVac vaccine of the participants whose antibody level was measured was 128.85 U/ml, the antibody level measured 6 months after the 2nd dose of vaccine was 60.50 U/ml of the participants who did not receive the 3rd dose of CoronaVac vaccine, and those who had the 3rd dose of CoronaVac vaccine The antibody level of the participants, which was measured 1 month after the 3rd dose of vaccine, was found to be 2037.50 U/ml, and the antibody levels of the participants who had the 3rd dose of Biontech, measured 1 month after the 3rd dose of vaccine, were 16869.00 U/ml. It was determined that the antibody levels measured 6 months after the 2nd dose of vaccination of the participants who did not receive the third dose of vaccine were lower than the antibody levels measured 1 month after the 2nd dose of vaccine, but there was no statistically significant difference (p>0.05). The antibody levels of the group that received the 3rd dose of Biontech vaccine from the participants were found to be statistically significantly higher than the groups that did not receive the 3rd dose of vaccine and the 3rd dose of CoronaVac vaccine (p<0.001). Conclusion: It was determined that the side effects that developed after CoronaVac vaccine were mild to moderate. It is predicted that the CoronaVac vaccine can be safely administered to individuals. The antibodies formed as a result of the vaccine show a decrease after a certain period of time, so a booster dose was considered necessary. It was determined that the immune response of the participants who were vaccinated with two doses of CoronaVac and who preferred the 3rd dose vaccine as the mRNA vaccine was much higher than the participants who preferred the 3rd dose vaccine as CoronaVac. Keywords: Sars-CoV-2, COVID-19 vaccines, advers effect, antibodies
Açıklama
Anahtar Kelimeler
Sars-CoV-2, COVID-19 Aşıları, İstenmeyen etkiler, Antikorlar, Sars-CoV-2, COVID-19 vaccines, Advers effect, Antibodies
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Can, A. (2022). Evaluation of post vaccine adverse effects and antibody levels observed after COVİD-19 vaccine administration in hospital staff. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Dahili Tıp Bilimleri Bölümü Halk Sağlığı Anabilim Dalı, Konya.
